ELUXADOLINE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for eluxadoline and what is the scope of patent protection?
Eluxadoline
is the generic ingredient in two branded drugs marketed by Aurobindo Pharma, Zydus Pharms, and Abbvie, and is included in three NDAs. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound. There are two tentative approvals for this compound.
Summary for ELUXADOLINE
| International Patents: | 153 |
| US Patents: | 14 |
| Tradenames: | 2 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 32 |
| Clinical Trials: | 10 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ELUXADOLINE |
| What excipients (inactive ingredients) are in ELUXADOLINE? | ELUXADOLINE excipients list |
| DailyMed Link: | ELUXADOLINE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ELUXADOLINE
Generic Entry Date for ELUXADOLINE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ELUXADOLINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Devintec Sagl | NA |
| Allergan | Phase 3 |
| Temple University | Phase 2/Phase 3 |
Generic filers with tentative approvals for ELUXADOLINE
| Applicant | Application No. | Strength | Dosage Form |
| ⤷ Start Trial | ⤷ Start Trial | 100MG | TABLET;ORAL |
| ⤷ Start Trial | ⤷ Start Trial | 75MG | TABLET;ORAL |
| ⤷ Start Trial | ⤷ Start Trial | 100MG | TABLET; ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for ELUXADOLINE
| Drug Class | mu-Opioid Receptor Agonist |
| Mechanism of Action | Opioid mu-Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for ELUXADOLINE
Paragraph IV (Patent) Challenges for ELUXADOLINE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VIBERZI | Tablets | eluxadoline | 75 mg and 100 mg | 206940 | 6 | 2019-05-28 |
US Patents and Regulatory Information for ELUXADOLINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | VIBERZI | eluxadoline | TABLET;ORAL | 206940-002 | May 27, 2015 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Abbvie | VIBERZI | eluxadoline | TABLET;ORAL | 206940-002 | May 27, 2015 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Abbvie | VIBERZI | eluxadoline | TABLET;ORAL | 206940-001 | May 27, 2015 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ELUXADOLINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | VIBERZI | eluxadoline | TABLET;ORAL | 206940-002 | May 27, 2015 | ⤷ Start Trial | ⤷ Start Trial |
| Abbvie | VIBERZI | eluxadoline | TABLET;ORAL | 206940-002 | May 27, 2015 | ⤷ Start Trial | ⤷ Start Trial |
| Abbvie | VIBERZI | eluxadoline | TABLET;ORAL | 206940-001 | May 27, 2015 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ELUXADOLINE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Allergan Pharmaceuticals International Limited | Truberzi | eluxadoline | EMEA/H/C/004098Truberzi is indicated in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS D). | Withdrawn | no | no | no | 2016-09-19 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ELUXADOLINE
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2014241076 | ⤷ Start Trial | |
| Brazil | 112015022753 | ⤷ Start Trial | |
| Canada | 2906472 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ELUXADOLINE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1725537 | 2017C/003 | Belgium | ⤷ Start Trial | PRODUCT NAME: ELUXADOLINE OF EEN FARMACEUTISCH AANVAARDBAAR ENANTIOMEER, DIASTEREOMEER, RACEMAAT OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU1/16/1126 20160921 |
| 1725537 | PA2017005,C1725537 | Lithuania | ⤷ Start Trial | PRODUCT NAME: ELUKSADOLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINAS ENANTIOMERAS, DIASTEREOMERAS, RACEMATAS ARBA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1126 20160919 |
| 1725537 | 122017000009 | Germany | ⤷ Start Trial | PRODUCT NAME: ELUXADOLIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1126 20160919 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
